Transcept Pharmaceuticals (TSPT) 1.70 $TSPT
Migraine - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/xq8n9b/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Migraine - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ache Laboratorios Farmaceuticos - Alder Biopharmaceuticals - Allergan - Amgen - Astellas Pharma - Avanir Pharmaceuticals - BioDelivery Sciences - Biofrontera - Bristol-Myers Squibb - D-Pharm - Eli Lilly and Company - Heptares Therapeutics - Impax Laboratories - IntelGenx - Istituto Italiano di Tecnologia - Medestea Research & Production - Merck & Co - Nektar Therapeutics - Northern Light Pharmaceuticals - Paladin Labs - Pfizer - Pozen - Proreo Pharma - Questcor Pharmaceuticals - Revance Therapeutics - TheraJect - Transcept Pharmaceuticals - Trigemina - Vertex Pharmaceuticals Incorporated - iCeutica For more information visit http://www.researchandmarkets.com/research/xq8n9b/migraine
VRTX: 113.66 (+4.03), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), NKTR: 13.54 (-0.14), AGN: 229.49 (+1.87), IPXL: 39.51 (+0.69), ALDR: 26.06 (+0.18), QCOR: 93.60 (+1.52), MRK: 58.81 (-0.07), TSPT: 1.70 (-0.04), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15)
Paratek Pharmaceuticals Completes Merger With Transcept Pharmaceuticals
GlobeNewswire - Thu Oct 30, 12:31PM CDT
Paratek Pharmaceuticals, Inc. (Nasdaq
RTK) and Transcept Pharmaceuticals, Inc. (Nasdaq:TSPT) (through October 30) today announced the two companies have completed their merger effective as of October 30, 2014.
TSPT: 1.70 (-0.04), PRTK: 26.95 (+0.65)
Transcept Announces Results of Special Meeting
PR Newswire - Tue Oct 28, 3:15PM CDT
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today that, based upon the final vote count certified by the independent inspector of elections for the special meeting of stockholders held October 28, 2014, shareholders approved all of the merger-related proposals, including: (i) the merger and issuance of Transcept common stock pursuant to the Agreement and Plan of Merger and Reorganization, dated June 30, 2014, by and among Transcept, Tigris Merger Sub, Inc., Tigris Acquisition Sub, LLC and Paratek Pharmaceuticals, Inc., (ii) effecting a one-for-twelve reverse stock split of Transcept common stock, and (iii) changing the name of the Company from "Transcept Pharmaceuticals, Inc." to "Paratek Pharmaceuticals, Inc."
TSPT: 1.70 (-0.04), PRTK: 26.95 (+0.65)
Transcept Declares Special Dividend Of $12.79 Million And Additional Contingent Future Amounts In Connection With Its Merger With Paratek Pharmaceuticals
PR Newswire - Tue Oct 14, 4:11PM CDT
Transcept Pharmaceuticals, Inc. (NASDAQ: TSPT) announced today that its board of directors declared a special dividend, in connection with its merger with Paratek Pharmaceuticals, Inc., in the initial cash amount of $0.6674 per share on Transcept's common stock and the right to receive certain contingent cash amounts, in the future, on a pro rata basis, consisting of: (i) one hundred percent of any payments received by Transcept on or prior to the second anniversary of the closing date of the merger pursuant to the United States License and Collaboration Agreement, dated July 31, 2009, as amended November 1, 2011, by and between Transcept and Purdue Pharmaceutical Products L.P., (ii) one hundred percent of any payments received by Transcept pursuant to the Termination Agreement and Release, dated September 19, 2014, by and between Transcept and Shin Nippon Biomedical Laboratories, Ltd., up to an aggregate of $2 million, (iii) ninety percent of any cash proceeds from a sale or disposition of Intermezzo (less all fees and expenses incurred by Transcept in connection with such sale or disposition following the closing date of the merger); provided such sale or disposition occurs, or a definitive written agreement with respect to such sale or disposition is entered into, prior to the second anniversary of the closing date of the merger, and (iv) the amount, if any, of the $3.0 million Intermezzo expense reserve to be deposited by Transcept at the closing of the merger that is remaining following the second anniversary of the closing date of the merger or upon the consummation of a sale or disposition of Intermezzo.
TSPT: 1.70 (-0.04), PRTK: 26.95 (+0.65)
Hercules' Solid Q3 Origination Boosts Yearly Growth Target - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 10:20AM CDT
Hercules (HTGC) released its portfolio update for third-quarter 2014, which reflected robust loan origination performance, supporting its goal to attain around $700???$850 million of annual new commitments for 2014.
ROP: 166.23 (+1.16), HTGC: 15.49 (+0.04), TSPT: 1.70 (-0.04), AVG: 20.73 (+0.25)
Strong Q3 Origination Activity Positions Hercules to Achieve Record Year-End Commitments
Business Wire - Mon Sep 29, 3:01PM CDT
--Six Hercules Portfolio Companies File IPO Registrations
ROP: 166.23 (+1.16), HTGC: 15.49 (+0.04), TSPT: 1.70 (-0.04), AVG: 20.73 (+0.25)
TSPT, BLDR, RAIL, PBIB, OC, APP Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Wed Sep 24, 3:41AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Transcept Pharmaceuticals Inc (NASDAQ:TSPT), Builders Firstsource Inc (NASDAQ:BLDR), Freightcar America Inc (NASDAQ:RAIL), Porter Bancorp Inc (NASDAQ BIB), Owens Corning (NYSE:OC), Appalaches Resources Inc (NYSE:APP) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
APP: 0.92 (+0.04), PBIB: 0.87 (+0.03), RAIL: 27.44 (+0.71), TSPT: 1.70 (-0.04), OC: 38.72 (+0.19), BLDR: 6.66 (+0.22)
Hercules Announces Second Quarter 2014 Financial Results and Quarterly Dividend of $0.31 per Share
Business Wire - Thu Aug 07, 3:01PM CDT
--Q2 2014 distributable net operating income, or "DNOI," of $21.0 million, or $0.34 per share, up 9.4% from Q2 2013
HTGC: 15.49 (+0.04), TSPT: 1.70 (-0.04)
Acquisitions, Study Results, Merger Agreements, and Completed Trial Recruitments - Analyst Notes on Cooper, Agenus, Transcept, CTI and ANI
PR Newswire - Fri Jul 04, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding The Cooper Companies Inc. (NYSE: COO), Agenus Inc. (NASDAQ: AGEN), Transcept Pharmaceuticals, Inc. (NASDAQ: TSPT), Cell Therapeutics, Inc. (NASDAQ: CTIC) and ANI Pharmaceuticals, Inc. (NASDAQ: ANIP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4446-100free.
AGEN: 5.03 (-0.01), ANIP: 62.69 (-0.43), TSPT: 1.70 (-0.04), CTIC: 2.23 (-0.02), COO: 165.20 (+2.18)
Nasdaq stocks posting largest volume increases
AP - Tue Jul 01, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
NSYS: 5.55 (+0.05), RIVR: 20.50 (-0.55), WBKC: 23.75 (+0.03), SPAR: 5.46 (unch), HFBC: 13.03 (-0.26), SPCHB: 1.21 (-0.01), SPCHA: 1.19 (unch), LBIX: 3.43 (-0.06), FFCO: 23.00 (-0.10), STAA: 6.76 (-0.02), TSPT: 1.70 (-0.04), LPCN: 5.91 (+0.40), WAYN: 13.85 (+0.22), IROQ: 16.70 (unch), ENVE: 19.28 (+0.57)
Paratek Appoints Michael Bigham as Chairman and CEO and Promotes Evan Loh to President and CMO
GlobeNewswire - Tue Jul 01, 5:30AM CDT
Paratek Pharmaceuticals, Inc., today announced that Michael F. Bigham, Partner at Abingworth LLP, has been appointed as Chairman of the Board of Directors and Chief Executive Officer. In addition, Dr. Evan Loh, Chief Medical Officer (CMO) at Paratek, has been promoted to President and Chief Medical Officer and will continue to serve on the Board of Directors. Dennis Molnar, the Company's previous CEO, will remain a member of the senior management team
TSPT: 1.70 (-0.04), PRTK: 26.95 (+0.65)
Transcept Pharmaceuticals and Paratek Pharmaceuticals Sign Merger Agreement
PR Newswire - Tue Jul 01, 5:15AM CDT
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) and Paratek Pharmaceuticals, Inc., a privately-held biopharmaceutical company, announced today that they have entered into a definitive merger agreement under which the stockholders of Paratek will become the majority owners of Transcept and the operations of Transcept and Paratek will be combined. As part of the proposed transaction, new investors (including The Baupost Group, Abingworth LLP, and other institutional investors); certain Transcept stockholders (including InterWest Ventures and Roumell Asset Management); and certain Paratek stockholders (including Omega Funds, HBM Healthcare Investments and Aisling Capital) will invest approximately $93 million in the combined organization.
TSPT: 1.70 (-0.04)
Migraine - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/xq8n9b/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Migraine - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ache Laboratorios Farmaceuticos - Alder Biopharmaceuticals - Allergan - Amgen - Astellas Pharma - Avanir Pharmaceuticals - BioDelivery Sciences - Biofrontera - Bristol-Myers Squibb - D-Pharm - Eli Lilly and Company - Heptares Therapeutics - Impax Laboratories - IntelGenx - Istituto Italiano di Tecnologia - Medestea Research & Production - Merck & Co - Nektar Therapeutics - Northern Light Pharmaceuticals - Paladin Labs - Pfizer - Pozen - Proreo Pharma - Questcor Pharmaceuticals - Revance Therapeutics - TheraJect - Transcept Pharmaceuticals - Trigemina - Vertex Pharmaceuticals Incorporated - iCeutica For more information visit http://www.researchandmarkets.com/research/xq8n9b/migraine
VRTX: 113.66 (+4.03), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), NKTR: 13.54 (-0.14), AGN: 229.49 (+1.87), IPXL: 39.51 (+0.69), ALDR: 26.06 (+0.18), QCOR: 93.60 (+1.52), MRK: 58.81 (-0.07), TSPT: 1.70 (-0.04), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15)
Paratek Pharmaceuticals Completes Merger With Transcept Pharmaceuticals
GlobeNewswire - Thu Oct 30, 12:31PM CDT
Paratek Pharmaceuticals, Inc. (Nasdaq
RTK) and Transcept Pharmaceuticals, Inc. (Nasdaq:TSPT) (through October 30) today announced the two companies have completed their merger effective as of October 30, 2014. TSPT: 1.70 (-0.04), PRTK: 26.95 (+0.65)
Transcept Announces Results of Special Meeting
PR Newswire - Tue Oct 28, 3:15PM CDT
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today that, based upon the final vote count certified by the independent inspector of elections for the special meeting of stockholders held October 28, 2014, shareholders approved all of the merger-related proposals, including: (i) the merger and issuance of Transcept common stock pursuant to the Agreement and Plan of Merger and Reorganization, dated June 30, 2014, by and among Transcept, Tigris Merger Sub, Inc., Tigris Acquisition Sub, LLC and Paratek Pharmaceuticals, Inc., (ii) effecting a one-for-twelve reverse stock split of Transcept common stock, and (iii) changing the name of the Company from "Transcept Pharmaceuticals, Inc." to "Paratek Pharmaceuticals, Inc."
TSPT: 1.70 (-0.04), PRTK: 26.95 (+0.65)
Transcept Declares Special Dividend Of $12.79 Million And Additional Contingent Future Amounts In Connection With Its Merger With Paratek Pharmaceuticals
PR Newswire - Tue Oct 14, 4:11PM CDT
Transcept Pharmaceuticals, Inc. (NASDAQ: TSPT) announced today that its board of directors declared a special dividend, in connection with its merger with Paratek Pharmaceuticals, Inc., in the initial cash amount of $0.6674 per share on Transcept's common stock and the right to receive certain contingent cash amounts, in the future, on a pro rata basis, consisting of: (i) one hundred percent of any payments received by Transcept on or prior to the second anniversary of the closing date of the merger pursuant to the United States License and Collaboration Agreement, dated July 31, 2009, as amended November 1, 2011, by and between Transcept and Purdue Pharmaceutical Products L.P., (ii) one hundred percent of any payments received by Transcept pursuant to the Termination Agreement and Release, dated September 19, 2014, by and between Transcept and Shin Nippon Biomedical Laboratories, Ltd., up to an aggregate of $2 million, (iii) ninety percent of any cash proceeds from a sale or disposition of Intermezzo (less all fees and expenses incurred by Transcept in connection with such sale or disposition following the closing date of the merger); provided such sale or disposition occurs, or a definitive written agreement with respect to such sale or disposition is entered into, prior to the second anniversary of the closing date of the merger, and (iv) the amount, if any, of the $3.0 million Intermezzo expense reserve to be deposited by Transcept at the closing of the merger that is remaining following the second anniversary of the closing date of the merger or upon the consummation of a sale or disposition of Intermezzo.
TSPT: 1.70 (-0.04), PRTK: 26.95 (+0.65)
Hercules' Solid Q3 Origination Boosts Yearly Growth Target - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 10:20AM CDT
Hercules (HTGC) released its portfolio update for third-quarter 2014, which reflected robust loan origination performance, supporting its goal to attain around $700???$850 million of annual new commitments for 2014.
ROP: 166.23 (+1.16), HTGC: 15.49 (+0.04), TSPT: 1.70 (-0.04), AVG: 20.73 (+0.25)
Strong Q3 Origination Activity Positions Hercules to Achieve Record Year-End Commitments
Business Wire - Mon Sep 29, 3:01PM CDT
--Six Hercules Portfolio Companies File IPO Registrations
ROP: 166.23 (+1.16), HTGC: 15.49 (+0.04), TSPT: 1.70 (-0.04), AVG: 20.73 (+0.25)
TSPT, BLDR, RAIL, PBIB, OC, APP Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Wed Sep 24, 3:41AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Transcept Pharmaceuticals Inc (NASDAQ:TSPT), Builders Firstsource Inc (NASDAQ:BLDR), Freightcar America Inc (NASDAQ:RAIL), Porter Bancorp Inc (NASDAQ
BIB), Owens Corning (NYSE:OC), Appalaches Resources Inc (NYSE:APP) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: APP: 0.92 (+0.04), PBIB: 0.87 (+0.03), RAIL: 27.44 (+0.71), TSPT: 1.70 (-0.04), OC: 38.72 (+0.19), BLDR: 6.66 (+0.22)
Hercules Announces Second Quarter 2014 Financial Results and Quarterly Dividend of $0.31 per Share
Business Wire - Thu Aug 07, 3:01PM CDT
--Q2 2014 distributable net operating income, or "DNOI," of $21.0 million, or $0.34 per share, up 9.4% from Q2 2013
HTGC: 15.49 (+0.04), TSPT: 1.70 (-0.04)
Acquisitions, Study Results, Merger Agreements, and Completed Trial Recruitments - Analyst Notes on Cooper, Agenus, Transcept, CTI and ANI
PR Newswire - Fri Jul 04, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding The Cooper Companies Inc. (NYSE: COO), Agenus Inc. (NASDAQ: AGEN), Transcept Pharmaceuticals, Inc. (NASDAQ: TSPT), Cell Therapeutics, Inc. (NASDAQ: CTIC) and ANI Pharmaceuticals, Inc. (NASDAQ: ANIP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4446-100free.
AGEN: 5.03 (-0.01), ANIP: 62.69 (-0.43), TSPT: 1.70 (-0.04), CTIC: 2.23 (-0.02), COO: 165.20 (+2.18)
Nasdaq stocks posting largest volume increases
AP - Tue Jul 01, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
NSYS: 5.55 (+0.05), RIVR: 20.50 (-0.55), WBKC: 23.75 (+0.03), SPAR: 5.46 (unch), HFBC: 13.03 (-0.26), SPCHB: 1.21 (-0.01), SPCHA: 1.19 (unch), LBIX: 3.43 (-0.06), FFCO: 23.00 (-0.10), STAA: 6.76 (-0.02), TSPT: 1.70 (-0.04), LPCN: 5.91 (+0.40), WAYN: 13.85 (+0.22), IROQ: 16.70 (unch), ENVE: 19.28 (+0.57)
Paratek Appoints Michael Bigham as Chairman and CEO and Promotes Evan Loh to President and CMO
GlobeNewswire - Tue Jul 01, 5:30AM CDT
Paratek Pharmaceuticals, Inc., today announced that Michael F. Bigham, Partner at Abingworth LLP, has been appointed as Chairman of the Board of Directors and Chief Executive Officer. In addition, Dr. Evan Loh, Chief Medical Officer (CMO) at Paratek, has been promoted to President and Chief Medical Officer and will continue to serve on the Board of Directors. Dennis Molnar, the Company's previous CEO, will remain a member of the senior management team
TSPT: 1.70 (-0.04), PRTK: 26.95 (+0.65)
Transcept Pharmaceuticals and Paratek Pharmaceuticals Sign Merger Agreement
PR Newswire - Tue Jul 01, 5:15AM CDT
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) and Paratek Pharmaceuticals, Inc., a privately-held biopharmaceutical company, announced today that they have entered into a definitive merger agreement under which the stockholders of Paratek will become the majority owners of Transcept and the operations of Transcept and Paratek will be combined. As part of the proposed transaction, new investors (including The Baupost Group, Abingworth LLP, and other institutional investors); certain Transcept stockholders (including InterWest Ventures and Roumell Asset Management); and certain Paratek stockholders (including Omega Funds, HBM Healthcare Investments and Aisling Capital) will invest approximately $93 million in the combined organization.
TSPT: 1.70 (-0.04)
